• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Almac Group

    Alcami

    Syngene

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Almac Group

    Adare Pharma Solutions

    Aphena Pharma Solutions

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    New Supply Chain Considerations in Response to COVID-19

    Cell & gene therapy companies have faced unique challenges due to the nature of their therapies, this is especially true for autologous cell therapies.

    New Supply Chain Considerations in Response to COVID-19
    Related CONTENT
    • Catalent Acquires Delphi Genetics
    • MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement
    • G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing
    • Century Therapeutics Significantly Expands Capabilities
    • Charles River Acquires CDMO Cognate BioServices
    Mark Stielow, Senior Director of Cell Manufacturing & Technical Operations, Adaptimmune06.10.20
    Healthcare organizations across the globe have adapted to varying degrees and in a multitude of ways to the COVID-19 pandemic. Elective procedures have been curtailed or deprioritized, medical staff have often been re-deployed to the “front lines,” and supply chains have been thrown into turmoil.

    Cell & gene therapy (CGT) companies have faced unique challenges due to the nature of their therapies. This has been especially true for autologous cell therapies, where the pandemic’s impact has challenged the intricate and complex supply chains coordinating patients, practitioners, and manufacturers. These autologous therapies, such as Adaptimmune’s SPEAR T-cells, generally start with the collection of leukocytes (white blood cells) from patients being treated for various types of cancers. The cells, collected by a process called apheresis, are shipped to a centralized manufacturing site. In the case of Adaptimmune’s therapies, the T-cells are then isolated, genetically-modified, and expanded in cell culture to produce engineered SPEAR T-cells. These engineered SPEAR T-cells, with enhanced functionality to recognize and attack the patient’s specific type of cancer, are then infused back into the patients.

    This “one patient - one batch” manufacturing strategy requires a broad range of specialized raw materials and consumables, flexible manufacturing capacity, and a highly skilled workforce for cell processing, testing, batch release, and product logistics.

    Unique Considerations for Autologous Cell Therapy Companies  

    While CGT companies have remained committed to manufacturing and delivering these critical life-sustaining therapies during the pandemic, several challenges require proactive and intensive mitigation. Foremost is the greater volatility in patient’s ability to travel in conjunction with access to clinical sites, both for the initial apheresis and for the subsequent infusion of the engineered cells, due to very real concerns regarding potential exposure to COVID-19 while in travel or at the treatment center. Patient scheduling can also be disrupted by the availability of healthcare professionals who may have been re-deployed to support their colleagues on the front line of the pandemic. Even when patients and their healthcare providers can keep their appointments, disruptions to commercial airline schedules can put the timely transport of cell materials between the clinic and the manufacturing site (and vice versa) at risk.

    The volatility in patient scheduling leads directly to higher variability in manufacturing scheduling, which may already be challenged by the fluctuating availability of the workforce or by shortages in critical raw materials, components or even PPE supplies.

    Mitigating the Uncertainties

    It is essential for autologous CGT companies to find solutions to these and other issues, while at the same time protecting the safety and health of their own employees. At Adaptimmune, we have taken several steps to ensure the uninterrupted supply of our SPEAR T-cells under these challenging conditions as well as mitigate risk – both of which are in a process of continuous improvement. Though these steps have been effective to mitigate the risks and uncertainties known to us in the current global supply climate, we continue to take proactive steps to ensure we can continue to deliver life-sustaining therapies to people with cancer.  

    For example, we are exploring alternate apheresis centers (separate from the treatment sites) that may be closer to the patient and not as heavily impacted as the large hospitals where treatment steps for our therapies are typically performed. This may make the patient journey easier in a way that also mitigates potential exposure to COVID-19 at large treatment centers. We are also decoupling the initial collection of T-cells from the subsequent re-infusion of engineered T-cells by manufacturing and storing cells to be infused later, when the clinical site is better able to accommodate the patient and procedure.

    To address potential disruptions to air transportation routes, we are utilizing ground transportation in the Eastern United States, whenever possible. When this is not feasible, or the distances are too great to ship the materials safely by ground, we have established contingency plans with our logistics partner to transport cells via chartered flights if commercial flights are unavailable.

    To mitigate potential shortages in raw materials and components, we began increasing our inventories as early as February 2020 for critical materials. This action, in conjunction with our secondary source planning, has enabled us to significantly increase our safety stock levels to carry us through intermittent disruptions.
     
    Finally, to keep our employees safe we implemented a work-from-home policy for all employees not directly necessary for product supply; thereby reducing the risk of COVID-19 transmission for those employees required to be on-site. For those employees on-site, we adapted our procedures to be consistent with the CDC/OSHA/WHO guidelines, including enforced social distancing, increased frequency and extent of cleaning for all areas, requiring the use of masks at all times, implementing temperature checks upon entering the facilities, and rapid tracking/tracing of any employees with potential symptoms to enable broader, temporary self-quarantines to stem any potential viral transmission.

    Being Prepared for Anything
     
    Like many other companies, we are adapting our supply chain planning processes to ensure we have everything needed for manufacturing, and we are increasing communications with respect to operations to keep our facilities and transportation running safely and effectively.

    The COVID-19 pandemic has challenged all supply chain professionals to do what is required to maintain critical operations during unprecedented, global disruptions. At Adaptimmune and across the CGT industry, CGT professionals are finding ways to provide critical therapies to people with cancer. Ultimately, we will emerge with stronger supply chains and the confidence that these complex manufacturing processes can continue to operate in the most trying of circumstances.

    Mark Stielow is the Senior Director of Cell Manufacturing & Technical Operations at Adaptimmune. Mark holds a Bachelor’s degree in Chemical Engineering from the University of Wisconsin, and a Masters of Management degree from the Northwestern Kellogg Graduate School.
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement
    G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing
    Century Therapeutics Significantly Expands Capabilities Century Therapeutics Significantly Expands Capabilities
    Charles River Acquires CDMO Cognate BioServices Charles River Acquires CDMO Cognate BioServices
    AbbVie, Caribou Ink CAR-T Collaboration AbbVie, Caribou Ink CAR-T Collaboration
    FDA Approves BMS CAR-T Cell Therapy FDA Approves BMS CAR-T Cell Therapy
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Paragon Biosciences Expands Cell and Gene Therapy Platform Paragon Biosciences Expands Cell and Gene Therapy Platform
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    The Future of Vaccines and Biologics The Future of Vaccines and Biologics
    Lonza Launches Cryopreserved Leukopaks Lonza Launches Cryopreserved Leukopaks
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    Capricor, Lonza Enter CAP-1002 Development Agreement Capricor, Lonza Enter CAP-1002 Development Agreement
    Adagene Achieves CAR-T Collaboration Milestone  Adagene Achieves CAR-T Collaboration Milestone

    Related Expert's Opinion

    • Biologics, Proteins, Vaccines | Cold Chain Management | Logistics | Supply Chain
      Rising to The Occasion: The High Stakes of Vaccine Transport

      Rising to The Occasion: The High Stakes of Vaccine Transport

      How logistical precision can ensure safe and efficient delivery of the COVID-19 vaccine.
      Bill Brooks, Vice President of North America Transportation Portfolio at Capgemini 11.04.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    • Biologics, Proteins, Vaccines | Drug Development | Information Technology
      Speeding Vaccine Development with Advanced Analytics

      Speeding Vaccine Development with Advanced Analytics

      Having immediate access to wide ranging resources of data can help speed the COVID-19 vaccine development process
      Dr. Shlomi Madar, VP of Healthcare Solutions, Signals Analytics 04.15.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      Robust Response to COVID-19 Demand

      Robust Response to COVID-19 Demand

      What it’s going to take to develop, scale-up, and manufacture the products needed to address the COVID-19 outbreak.
      Christa Myers, Pharmaceutical Market Sector Lead, CRB 03.31.20

    • Biologics, Proteins, Vaccines | Drug Development
      Immunogenicity Assessment of Gene Therapy Compounds

      Immunogenicity Assessment of Gene Therapy Compounds

      Dr. Kromminga of BioAgilytix discusses testing challenges and evolving trends in gene therapy.
      Dr. Arno Kromminga, global chief scientific officer, BioAgilytix 11.27.19

    • Biologics, Proteins, Vaccines | Clinical Trials
      Advanced Therapies: Adding a New Layer of Complexity to Clinical Trials

      Advanced Therapies: Adding a New Layer of Complexity to Clinical Trials

      Overcoming the challenges of a new and changing clinical trial landscape
      Erin Finot, Global Head of Immuno-Oncology, IQVIA Biotech 11.18.19


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Scale-up/Technology Transfer
      The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing

      The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing

      Cell and gene therapy facilities face a unique set of challenges as they scale towards commercial production and require equally unique solutions
      Peter Walters , Lead Process Engineer, CRB USA 11.11.19

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Continued and Consistent Investment in Manufacturing Facilities

      Continued and Consistent Investment in Manufacturing Facilities

      As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge
      Ryan Carpentier, Executive Director of Business Development, Cryoport 09.23.19

    • Biologics, Proteins, Vaccines | Cold Chain Management | Drug Development | Supply Chain
      CAR T for Large Tumors: The Next Frontier?

      CAR T for Large Tumors: The Next Frontier?

      Ryan Carpentier of Cryoport discusses the successes and the challenges these exciting new therapies present
      Ryan Carpentier, Executive Director of Business Development at Cryoport 09.10.19


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | GMPs/GCPs | Regulatory Affairs
      Knowledge Sharing in the Development and Delivery of Biologics

      Knowledge Sharing in the Development and Delivery of Biologics

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development
      Fran L. DeGrazio, Vice President, Scientific Affairs & Technical Services, West Pharmaceutical Services, Inc. 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Missing Piece in Rare-Disease Drug Development

      The Missing Piece in Rare-Disease Drug Development

      More genetics expertise is crucial in getting these drugs to market.
      Jill Johnston, President, Site Activation Solutions, WCG Clinical Services and Karmen Trzupek, Director, Ocular & Rare Disease Genetics Services, InformedDNA 08.22.18

    • Biologics, Proteins, Vaccines
      Technological Arms Race Could Improve Bio Process Mfg. Efficiency

      Technological Arms Race Could Improve Bio Process Mfg. Efficiency

      Experts warn bio industry needs to do more to create a sustainable pipeline of talent
      06.29.18

    Trending
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Spark Therapeutics Appoints CTO
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Catalent Acquires Delphi Genetics
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login